CSL Shares Fall as It Enters Long-Term Agreement With Pan American Health Organization for Influenza Vaccines
MT Newswires Live
Mar 11
CSL (ASX:CSL) shares were down nearly 2% in recent trading on Wednesday after it said in a late Tuesday statement that CSL Seqirus entered into a long-term agreement with the Pan American Health Organization Regional Revolving Fund to advance influenza protection in the Latin America region.
CSL Seqirus will supply its differentiated portfolio of influenza vaccines, working with its long-term production partner, the Argentina-based Sinergium Biotech, to localize vaccine filling and distribution.
CSL Seqirus and Sinergium will invest $10 million to enable the transfer of technology capability, which will add to the recent $25 million investment by Sinergium Biotech to increase local filling capacity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.